Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Surgery Partners (SGRY) Cash & Equivalents (2016 - 2025)

Surgery Partners' Cash & Equivalents history spans 12 years, with the latest figure at $239.9 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 10.98% year-over-year to $239.9 million; the TTM value through Dec 2025 reached $239.9 million, down 10.98%, while the annual FY2025 figure was $239.9 million, 10.98% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $239.9 million at Surgery Partners, up from $203.4 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $541.9 million in Q1 2021 and bottomed at $154.8 million in Q3 2022.
  • The 5-year median for Cash & Equivalents is $238.0 million (2023), against an average of $271.9 million.
  • The largest annual shift saw Cash & Equivalents surged 178.47% in 2021 before it crashed 53.15% in 2022.
  • A 5-year view of Cash & Equivalents shows it stood at $389.9 million in 2021, then decreased by 27.44% to $282.9 million in 2022, then tumbled by 30.75% to $195.9 million in 2023, then surged by 37.57% to $269.5 million in 2024, then decreased by 10.98% to $239.9 million in 2025.
  • Per Business Quant, the three most recent readings for SGRY's Cash & Equivalents are $239.9 million (Q4 2025), $203.4 million (Q3 2025), and $250.1 million (Q2 2025).